{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:27:10Z","timestamp":1794000430490,"version":"4.8.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.chest.2026.09.029","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:09:28Z","timestamp":1790687368000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Antifibrotic Dosing Patterns With Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis in Real-World Data Sources"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0003-9971","authenticated-orcid":false,"given":"Aparna C.","family":"Swaminathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna R.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Shrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Gebre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Wruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.chest.2026.09.029_bib1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"10.1016\/j.chest.2026.09.029_bib2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.chest.2026.09.029_bib3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2026.09.029_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00084-2018","article-title":"Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study","volume":"4","author":"Cottin","year":"2018","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.chest.2026.09.029_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12931-022-01974-2","article-title":"Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial","volume":"23","author":"Cottin","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.chest.2026.09.029_bib6","series-title":"OFEV (nintedanib capsules) [package insert]","year":"2024"},{"key":"10.1016\/j.chest.2026.09.029_bib7","series-title":"ESBRIET (pirfenidone) [package insert]","year":"2023"},{"issue":"1","key":"10.1016\/j.chest.2026.09.029_bib8","article-title":"Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials","volume":"5","author":"Nathan","year":"2018","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.chest.2026.09.029_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107015","article-title":"Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis","volume":"204","author":"Porse","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2026.09.029_bib10","article-title":"Clinical outcomes of dose modification during pirfenidone treatment for IPF: a nationwide post-marketing surveillance study","volume":"13","author":"Kang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.chest.2026.09.029_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241280704","article-title":"Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States","volume":"18","author":"Qiu","year":"2024","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.chest.2026.09.029_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s12890-025-03916-2","article-title":"Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study","volume":"25","author":"Lalla","year":"2025","journal-title":"BMC Pulm Med"},{"issue":"9779","key":"10.1016\/j.chest.2026.09.029_bib13","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.chest.2026.09.029_bib14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2026.09.029_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261684","article-title":"Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real-world study","volume":"16","author":"Lee","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.chest.2026.09.029_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12931-024-02883-2","article-title":"The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry","volume":"25","author":"Lee","year":"2024","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.chest.2026.09.029_bib17","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1513\/AnnalsATS.202001-035SD","article-title":"The Pulmonary Fibrosis Foundation Patient Registry: Rationale, design, and methods","volume":"17","author":"Wang","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.chest.2026.09.029_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12931-015-0276-5","article-title":"Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis","volume":"16","author":"Corte","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.chest.2026.09.029_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01533-2025","article-title":"The impact of frailty on prescribing patterns and medication tolerability in interstitial lung disease","author":"Wong","year":"2025","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2026.09.029_bib20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12890-023-02630-1","article-title":"Overall drug treatment of idiopathic pulmonary fibrosis patients from national registries\u2014a real-world study from Finland","volume":"23","author":"Kaunisto","year":"2023","journal-title":"BMC Pulm Med"},{"issue":"9","key":"10.1016\/j.chest.2026.09.029_bib21","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.3390\/jcm13092727","article-title":"Understanding patterns of adherence to antifibrotic treatment in idiopathic pulmonary fibrosis: insights from an Italian prospective cohort study","volume":"13","author":"Iommi","year":"2024","journal-title":"J Clin Med"},{"issue":"26","key":"10.1016\/j.chest.2026.09.029_bib22","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922606719X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922606719X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:58:06Z","timestamp":1793998686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236922606719X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"alternative-id":["S001236922606719X"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2026.09.029","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Antifibrotic Dosing Patterns With Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis in Real-World Data Sources","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}